| Literature DB >> 31481589 |
Johannes Czernin1, Ida Sonni2, Aria Razmaria2, Jeremie Calais2.
Abstract
In this article, we provide an overview of established and emerging conventional nuclear medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is rapidly expanding. Next, we review briefly nuclear theranostic approaches that have already entered or are about to enter clinical routine. Using some approximations and taking into account emerging applications, we also provide some simplified business forecasts for nuclear theranostics. We argue that an optimistic outlook by the nuclear medicine community is crucial to the growth of the specialty and emphasize the urgent need for training adaptations.Keywords: molecular imaging; nuclear medicine; theranostics
Mesh:
Substances:
Year: 2019 PMID: 31481589 DOI: 10.2967/jnumed.118.220558
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057